AI Insight
The U.S. Food and Drug Administration (FDA) has approved a label expansion for two drugs — Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) — for the treatment of adult patients with generalized myasthenia gravis (gMG). This approval was granted to the biopharmaceutical company argenx. The expansion broadens the eligible patient population who can be treated with these neonatal Fc receptor (FcRn) antagonist-based therapies, which work by reducing pathogenic IgG antibodies implicated in gMG.
Why it matters
Generalized myasthenia gravis is a chronic autoimmune neuromuscular disease causing debilitating muscle weakness, and this label expansion may provide more patients with access to a targeted therapeutic option. It represents a continued advancement in FcRn-targeting treatments for autoimmune conditions.
The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with (gMG). The expanded approval was granted to argenx.
Source: FDA approves label expansion for Vyvgart, Vyvgart Hytrulo for generalized myasthenia gravis